Viridian Therapeutics, Inc. (VRDN)

Viridian Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	102.83	155.58	42.3	45.9	24.85
Short-Term Investments	374.54	268.97	154.67	81.74	2
Cash & Cash Equivalents	477.37	424.55	196.97	127.64	26.85
Cash Growth	12.44%	115.55%	54.31%	375.47%	-57.03%
Receivables	0.1	0.1	0.45	0	0
Other Current Assets	9.01	6.52	2.75	1.97	2.89
Total Current Assets	486.48	431.17	200.16	129.61	29.74
Property, Plant & Equipment	3.34	2.94	2.06	0.79	0.52
Other Long-Term Assets	0.6	0.98	1.49	0.86	0
Total Long-Term Assets	3.95	3.92	3.55	1.64	0.52
Total Assets	490.42	435.09	203.71	131.26	30.26
Accounts Payable	2.24	14.23	2.33	0.67	1.1
Deferred Revenue	0.86	1.15	1.44	0.3	0
Current Debt	0	0	0	0	3.98
Other Current Liabilities	23.54	17.97	9.87	9.7	5.11
Total Current Liabilities	26.64	33.35	13.64	10.67	10.18
Long-Term Debt	20.21	4.65	0	0	4.33
Other Long-Term Liabilities	1.56	2.03	2.36	0.54	0
Total Long-Term Liabilities	21.77	6.68	2.36	0.54	4.33
Total Liabilities	48.4	40.03	15.99	11.22	14.51
Total Debt	20.21	4.65	0	0	8.3
Debt Growth	334.98%	-	-	-	-19.36%
Retained Earnings	-725.91	-488.17	-358.3	-278.89	-168.17
Comprehensive Income	0.34	-0.39	-0.16	-0.01	0
Shareholders' Equity	442.02	395.06	187.72	120.04	15.75
Net Cash / Debt	457.17	419.91	196.97	127.64	18.54
Net Cash / Debt Growth	8.87%	113.19%	54.31%	588.41%	-64.47%
Net Cash Per Share	10.21	13.09	16.53	35.88	8.88
Working Capital	459.84	397.82	186.53	118.94	19.56
Book Value Per Share	9.88	12.31	15.75	33.75	7.54

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).